Neurocrine CEO Kevin Gorman says the company learned to run lean for years after having to deal with major setbacks and layoffs. Now, the company increased its staff from about 110 in 2016 to about 375 this month as it prepares for commercialization of its recently approved drug Ingrezza.

Neurocrine CEO Kevin Gorman says the company learned to run lean for years after having to deal with major setbacks and layoffs. Now, the company increased its staff from about 110 in 2016 to about 375 this month as it prepares for commercialization of its recently approved drug Ingrezza.

— The weekend of April 7 was a tense one at the headquarters of Neurocrine Biosciences Inc...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129